Quietus
(Gefapixant)Phase 3Small molecule
Merck & Co.Gefapixant is used to treat chronic cough that persists for weeks or months without a known cause. It works by blocking a pain receptor in the throat that triggers the cough reflex.[1] Quietus is currently being investigated across 13 indications[3], with its most advanced program in Phase 3.[1]
Quietus is one of 379 small molecule programs targeting Respiratory tract infection. It is currently in Phase 3.
13
Indications
26
Total Trials
1
Active Trials
378
Competitors
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 12 indications
Competition
Competitive Landscape
1050 competitors in Asthma
#DrugCompanyPhaseTrials
1Quietus
Merck & Co.Phase 3
Veramyst
GSKPreclinical
Xolair
RochePreclinical
Cinqair
TevaPreclinical
Celexa
AbbViePreclinical
Spiriva
Boehringer IngelheimPreclinical
Qvar
Chiesi Farmaceutici S.p.A.Preclinical
Symbicort
AstraZenecaPreclinical
Atrovent
Boehringer IngelheimPreclinical
Tylenol
KKenvue Brands
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Chronic Cough12 trials
Show 9 more trials
Tics2 trials
Idiopathic Pulmonary Fibrosis2 trials
Gastric1 trial
8 more indications
Renal insufficiency1 trial
Endometriosis1 trial
Respiratory tract infection1 trial
Osteoarthritis1 trial
Stress urinary incontinence1 trial
Asthma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Gefapixant. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Mechanism of Action
- P2X Purinoceptor 3 Antagonist[2]
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company